#4-02. Breaking the Pain Barrier: The Promise of LEVI-04 in Knee Osteoarthritis (Lancet, 2026)

Are you struggling with the limited efficacy and adverse effects of current pain management strategies for knee osteoarthritis1? This episode delves into a phase 2, randomized, double-blind, placebo-controlled trial evaluating LEVI-04, a novel p75 neurotrophin receptor (p75NTR) fusion protein. Administered via monthly intravenous infusions, LEVI-04 significantly improved Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores compared to placebo at week . The most groundbreaking finding is that LEVI-04 achieved these significant analgesic benefits without increasing the incidence of severe joint pathologies, such as rapidly progressive osteoarthritis, which has historically plagued anti-nerve growth factor therapies. However, when critically appraising this study, clinicians should note that the safety follow-up period was relatively short at just 13 weeks post-primary endpoint, and the trial lacked a formal quality-of-life assessment. For physicians, this research is highly clinically relevant as it introduces a promising, safe, non-opioid therapeutic option that could profoundly change how we manage patients with refractory osteoarthritic pain in our daily practice.

Citation: Philip G Conaghan, Nathaniel Katz, Asger R Bihlet, Ali Guermazi, Dror Rom, Michael C Perkins, Bernadette Hughes, Claire Herholdt, Iwona Bombelka, Simon Westbrook. Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2026.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.